Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)

In the ph 3 PACIFIC study of unresectable, Stage III NSCLC pts without progression after chemoradiotherapy (CRT), durvalumab (durva) demonstrated significant improvements versus placebo (pbo) in the primary endpoints progression-free survival and overall survival, with manageable safety and no detrimental effect on pt-reported outcomes. We performed exploratory analyses to characterize patterns of disease progression, including the sites of first progression.

Source: International Journal of Radiation Oncology * Biology * Physics - September 18, 2019 Category: Radiology Authors: D. Raben, A. Rimner, S. Senan, H. Broadhurst, T. Pellas, P.A. Dennis, C. Faivre-Finn Source Type: research